JME
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1677/jme.0.0310241

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McGowan, E.
Right arrow Articles by Clarke, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McGowan, E.
Right arrow Articles by Clarke, C.
Journal of Molecular Endocrinology, Vol 31, Issue 2, 241-253
Copyright © 2003 by Society for Endocrinology


Articles

Cytoskeletal responsiveness to progestins is dependent on progesterone receptor A levels

EM McGowan, RP Weinberger, JD Graham, HD Hill, JA Hughes, GM O'Neill, and CL Clarke


Changes in the cell cytoskeleton occur in cell transformation and recent data suggest the involvement of ovarian hormones, which are implicated in cancer development and progression. In human breast and endometrial tumors, there is disrupted expression of progesterone receptor (PR) isoforms and predominance of one isoform, usually PRA. PRA predominance is an early event in carcinogenesis, and in cancers is associated with poor clinical features. Overexpression of PRA in vitro causes altered progestin regulation of cell morphology, suggesting that PRA overexpression may provoke deleterious changes in cell functioning. This study aimed to identify pathways of cytoskeleton regulation responsive to progestins and to determine whether these are perturbed when PRA is overexpressed to the levels seen in cancers. Progestin treatment of PR-positive breast cancer cells caused increased cell surface area whereas after induction of a stably integrated PRA construct, cells became rounded and the cell surface was decreased. The effect of PRA induction on cell rounding was reversed by the anti-progestin RU38486. Altered tropomyosin (Tm) isoforms were implicated in these morphological differences, as there was a PRA-mediated alteration in Tm5 isoform levels, and transfection of Tm5a mimicked progestin-mediated cell rounding in PRA-overexpressing cells. Ezrin was redistributed from the membrane to cytoplasmic locations in the presence of progestin, and discrete focal localization was evident in cells with PRA predominance. Progestin effects on the cytoskeleton in PRA-overexpressing cells provide evidence for novel endocrine regulation of aspects of actin microfilament composition, suggesting that changes in the cytoskeleton known to be associated with cancer development and progression may be regulated in part by altered PRA expression which develops early in carcinogenesis.


This article has been cited by other articles:


Home page
J Mol EndocrinolHome page
M. M White, I. Sheffer, J. Teeter, and E. M. Apostolakis
Hypothalamic progesterone receptor-A mediates gonadotropin surges, self priming and receptivity in estrogen-primed female mice
J. Mol. Endocrinol., January 1, 2007; 38(1): 35 - 50.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
P. A. Mote, R. L. Arnett-Mansfield, N. Gava, A. deFazio, B. Mulac-Jericevic, O. M. Conneely, and C. L. Clarke
Overlapping and Distinct Expression of Progesterone Receptors A and B in Mouse Uterus and Mammary Gland during the Estrous Cycle
Endocrinology, December 1, 2006; 147(12): 5503 - 5512.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
J. D. Graham, M. L. Yager, H. D. Hill, K. Byth, G. M. O'Neill, and C. L. Clarke
Altered Progesterone Receptor Isoform Expression Remodels Progestin Responsiveness of Breast Cancer Cells
Mol. Endocrinol., November 1, 2005; 19(11): 2713 - 2735.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the Society for Endocrinology.